PlumX Metrics
Embed PlumX Metrics

Visualization of activated T cells by OX40-ImmunoPET as a strategy for diagnosis of acute graft-versus-host disease

Cancer Research, ISSN: 1538-7445, Vol: 80, Issue: 21, Page: 4780-4790
2020
  • 25
    Citations
  • 0
    Usage
  • 15
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), mediated primarily by donor T cells that become activated and attack host tissues. Noninvasive strategies detecting T-cell activation would allow for early diagnosis and possibly more effective management of HCT recipients. PET imaging is a sensitive and clinically relevant modality ideal for GvHD diagnosis, and there is a strong rationale for the use of PET tracers that can monitor T-cell activation and expansion with high specificity. The TNF receptor superfamily member OX40 (CD134) is a cell surface marker that is highly specific for activated T cells, is upregulated during GvHD, and mediates disease pathogenesis. We recently reported the development of an antibody-based activated T-cell imaging agent targeting OX40. In the present study, we visualize the dynamics of OX40 expression in an MHC-mismatch mouse model of acute GvHD using OX40-immunoPET. This approach enabled visualization of T-cell activation at early stages of disease, prior to overt clinical symptoms with high sensitivity and specificity. This study highlights the potential utility of the OX40 PET imaging as a new strategy for GvHD diagnosis and therapy monitoring.

Bibliographic Details

Alam, Israt S; Simonetta, Federico; Scheller, Lukas; Mayer, Aaron T; Murty, Surya; Vermesh, Ophir; Nobashi, Tomomi W; Lohmeyer, Juliane K; Hirai, Toshihito; Baker, Jeanette; Lau, Kenneth H; Negrin, Robert; Gambhir, Sanjiv S

American Association for Cancer Research (AACR)

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know